AI drug discovery company Isomorphic Labs has raised a staggering $2.1 billion in funding led by Thrive Capital, with support from Google-backed momentum. The fresh cash is set to expand its AI drug design engine and push timelines for early clinical testing, now expected to start by late 2026, as the company targets faster routes to treating disease.
India’s drug regulator CDSCO has tightened rules for drug safety reporting. Pharma firms must file safety reports starting from the actual launch date of new drugs rather than the approval date. The regulator says this will better capture real-world safety signals. It also brings all forms and uses of a new drug under one consolidated safety report.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Japanese researchers have begun human trials for a drug designed to regrow teeth by activating dormant tooth buds. The approach could offer a more natural path to treating tooth loss, moving beyond today’s implants and dentures. Early findings look promising, and the team is targeting a potential release around 2030 if results hold up.
Japanese researchers say a medicine designed to regrow teeth is moving toward human clinical trials. The breakthrough could shift dental care from treatment and replacement toward true regeneration, offering hope for people affected by decay and tooth loss. While early, the planned studies mark an important step from lab results to real-world testing in patients.
India’s drug regulator has accelerated pharma innovation by cutting approval timelines by more than half. Clinical trial approvals will now take about 120-135 days, while marketing authorisations are cleared in under 150 days. The reforms also remove certain pre-clinical approval requirements, aiming to strengthen ease of doing business and speed product delivery.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
